The ABPI welcomes the opportunity to respond to the DH consultation on the Cancer Drugs Fund (CDF). ABPI and its member companies have closely followed the development and ongoing regional implementation of the interim CDF from October 2010 with interest and this has provided us with useful insights to help inform our response to this consultation. These insights are highlighted in italics where they are included in the submission.
This response has been developed in discussion with many of our member companies and also with the input and contribution of members of the ABPI Pharmaceutical Oncology Initiative (POI). The response has been approved by the ABPI Board of Management.
Download the ABPI response to the consultation on the cancer drugs fund (PDF, 345KB)